Hematological Disorders in EHPVO Patients

NCT07108023 | Not Yet Recruiting

• 1 other identifier: EHPVO-02
• Study Type: observational
• Target: 115
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver. This blockage can cause problems like an enlarged spleen, bleeding from swollen veins in the digestive system, and low blood cell counts. Many of these patients may have hidden blood disorders that increase the risk of clotting, such as myeloproliferative neoplasms (MPNs), antiphospholipid syndrome (APS), or paroxysmal nocturnal hemoglobinuria (PNH). This study will collect and analyze blood test results-such as complete blood count (CBC), liver function tests (LFTs), and clotting tests-from patients with EHPVO. The aim is to find patterns that may suggest an underlying blood disorder, even if the patient doesn't show obvious symptoms.By understanding these patterns early, doctors may be able to diagnose and treat the root causes of clotting in these patients more accurately, helping prevent complications and improve outcomes.

Conditions

Extrahepatic Portal Vein Obstruction (EHPVO); Thrombophilia; Myeloproliferative Neoplasms (MPN); Antiphospholipid Syndrome (APS); Paroxysmal Nocturnal Hemoglobinuria (PNH); Thrombocytopenia; Anemia; Leukopenia

Keywords

Portal vein thrombosis; EHPVO; Hypersplenism; Hematological disorders; Coagulation profile; Liver function tests; CBC; JAK2 mutation; Thrombosis in MPN; Cross-sectional study

Outcome Measures

Primary Outcomes (2)

• Frequency of hematological disorders in EHPVO patients

  The proportion of EHPVO Patients showing hematological disorders including cytopenias ( thrombocytopenia , anemia , leukopenia ) and coagulation disturbances based on retrospective laboratory data

  Over a retrospective period from 2020 to 2024

• Frequency of hematological disorders in EHPVO patients

  Over a retrospective period from 2020 to 2024

Study Arms (1)

EHPVO Patients

Patients diagnosed with extrahepatic portal vein obstruction (EHPVO) based on imaging (Doppler ultrasound, CT, or MRI) and with preserved liver function. This group will be assessed for hematological abnormalities, including cytopenias and coagulation disturbances, using retrospective laboratory data.

Other: No intervention (Observational Study)

Interventions

No intervention (Observational Study) OTHER

This is a retrospective observational study with no assigned intervention. Data will be collected from patient medical records only

EHPVO Patients

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients diagnosed with EHPVO between 2020 and 2024 in a tertiary care hospital in Cairo. Data will be collected retrospectively from medical records

You may qualify if:

• Age 18 years or older . Diagnosis of extra hepatic portal vein obstruction based on imaging ( Doppler, CT , MRI ) preserved liver function . Available complete medical records including CBC , LFTs and coagulation profile .

You may not qualify if:

• Patients with cirrhosis or intrahepatic portal hypertension • Incomplete or missing medical records • Patients with known hematologic malignancies or undergoing chemotherapy

Sponsors & Collaborators

• Rahab Nady: lead

Related Links

• Related Info

MeSH Terms

Conditions

Thrombophilia; Myeloproliferative Disorders; Antiphospholipid Syndrome; Hemoglobinuria, Paroxysmal; Thrombocytopenia; Anemia; Leukopenia; Hypersplenism; Hematologic Diseases

Interventions

Observation

Condition Hierarchy (Ancestors)

Hemic and Lymphatic Diseases; Bone Marrow Diseases; Autoimmune Diseases; Immune System Diseases; Anemia, Hemolytic; Myelodysplastic Syndromes; Blood Platelet Disorders; Cytopenia; Leukocyte Disorders; Splenic Diseases; Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Study Officials

• Mohamed Q Professor of internal medicine

  Assiut University

  PRINCIPAL INVESTIGATOR

• Maha M Dr Maha Mohamed Abdelaziz, Dr at Internal medicine

  Assiut University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Rehab N Dr Rehab Nady Ali

CONTACT

+201099703970; reeehabnady@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Assistant Lecturer

Study Record Dates

• First Submitted: July 31, 2025
• First Posted: August 6, 2025
• Study Start: August 1, 2025
• Primary Completion: December 1, 2025
• Study Completion: December 1, 2025
• Last Updated: August 6, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: IPD and supporting documents will be available starting 6 months after publication of the primary results and will remain available for up to 5 years after publication.
• Access Criteria: Access to the de-identified individual participant data (IPD), including CBC, LFTs, and coagulation profiles, will be granted to qualified researchers for academic and non-commercial purposes. Requests should be submitted to the Principal Investigator and will be reviewed on a case-by-case basis. A data use agreement may be required before access is granted.